Status:
UNKNOWN
UPLC-MS/MS Monitoring of Emicizumab Therapy
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Groupement Interrégional de Recherche Clinique et d'Innovation
Conditions:
Hemophilia A
Eligibility:
All Genders
Brief Summary
Emicizumab is a monoclonal bispecific antibody with a terminal half-life of 28 days which is now licensed in the treatment of severe haemophilia A with or without inhibitors. Some heterogeneity in res...
Eligibility Criteria
Inclusion
- Adult or child with Clinical diagnosis of severe hemophilia A (FVIII activity \< 1%) with or without inhibitor
- Clinical indication to emicizumab therapy
Exclusion
- Refusal to give informed consent
- acquired hemophilia A
- other inherited or acquired bleeding disorder
- bodyweight \< 10 kgs
Key Trial Info
Start Date :
April 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04472169
Start Date
April 13 2022
End Date
February 1 2024
Last Update
February 10 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Caen
Caen, France
2
Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU
Lille, France, 59037